Department of Pulmonary Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Indian J Pharmacol. 2012 Jan;44(1):131-3. doi: 10.4103/0253-7613.91887.
The war against cancer has seen a proliferation in armamentarium over the last decades. A new antineoplastic agent, trastuzumab, was synthesized in 1991 and gained United States Food and Drug Administration approval in 1998 for treatment of metastatic breast cancer. Cardiotoxicity manifesting as dilated cardiomyopathy is a rarely reported adverse effect of trastuzumab. We hereby report a case of dilated cardiomyopathy, which occurred following trastuzumab chemotherapy in a 32-year-old female. The patient responded to discontinuation of trastuzumab and standard medical treatment. Extensive search of Indian literature revealed no reported case of dilated cardiomyopathy occurring due to trastuzumab.
在过去的几十年里，抗癌之战中出现了大量的武器。一种新的抗肿瘤药物曲妥珠单抗于 1991 年合成，并于 1998 年获得美国食品和药物管理局批准用于治疗转移性乳腺癌。曲妥珠单抗表现为扩张型心肌病的心脏毒性是一种罕见的不良反应。我们在此报告一例 32 岁女性在曲妥珠单抗化疗后发生扩张型心肌病的病例。该患者对停用曲妥珠单抗和标准药物治疗有反应。对印度文献的广泛检索未发现因曲妥珠单抗而发生扩张型心肌病的报道病例。
